We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

By LabMedica International staff writers
Posted on 01 Mar 2015
Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis.

E. More...
faecalis, a bacterium inhabiting the gastrointestinal tracts of humans, is an important pathogen found in many infections including endocarditis, urinary tract infection, meningitis, and persistent infections associated with root canal treatment failure. The difficulty in E. faecalis treatment has been attributed to the lack of anti-infective strategies to eradicate its biofilm and to the frequent emergence of multidrug resistant strains.

Investigators at the Hebrew University of Jerusalem (Israel) evaluated the possibility of treating E. faecalis infections with specific bacteriophages, viruses that infect and destroy bacteria. To this end, they isolated an anti-E. faecalis and E. faecium phage, from effluents obtained from a Jerusalem (Israel), sewage treatment facility.

The EFDG1phage was visualized by electron microscopy. EFDG1 DNA coding sequences and phylogeny were determined by whole genome sequencing, which revealed that it belonged to the Spounavirinae subfamily of the Myoviridae phages, which includes promising candidates for therapy against Gram positive pathogens. This analysis also showed that the EFDG1 genome did not contain apparent harmful genes.

EFDG1 antibacterial efficacy was evaluated in vitro against planktonic and biofilm cultures. Results published in the February 6, 2015, online edition of the journal Applied and Environmental Microbiology showed that the phage displayed effective lytic activity against various E. faecalis and E. faecium isolates, regardless of their antibiotic resistance profile. Additionally, EFDG1 efficiently prevented ex vivo E. faecalis root canal infection.

Senior author Dr. Ronen Hazan, professor of dental sciences at the Hebrew University of Jerusalem, said, “The idea of using phages as antibacterial drugs is not new. Phage therapy was first proposed at the start of the 20th century, but then abandoned for various reasons, including the striking success of chemical antibiotics. Now we stand on the verge of a new era with the limitations of synthetic antibiotics and the emergence of antibiotic-resistant strains of bacteria. Thus it is the right time to look again into what Mother Nature offers in the battle against bacteria. As this research shows, bacteriophages may prove an effective tool in the development of much-needed new antimicrobial drugs.”

Hebrew University of Jerusalem

Related Links:

New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.